Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CACH RECEVA: Amlodipine for reversible cerebral vasoconstriction syndrome
2023-504547-14-01Phase 4Authorised
- Sponsor
- Helsinki University Hospital
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Reversible cerebral vasoconstriction syndrome (RCVS) comparing Amlodipine with Placebo (2 arms). Primary endpoint: Frequency of recurring headache. Planned start Sep 2026; status: authorised.
02
Drugs
amlodipine
03
Conditions
Reversible cerebral vasoconstriction syndrome (RCVS)
Beyond the preview
Go deeper on 2023-504547-14-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504547-14-01.